Go or no go? Valuable drugs set for FDA decisions
Upcoming US approval verdicts include inclisiran, valrox and risdiplam, but toxicity issues could scupper filgotinib.
A turn-up for Spectrum’s book
Poziotinib unexpectedly succeeds in a lung cancer niche, but competition from Takeda must be tracked closely.
Curevac muddies the Moderna/Arbutus waters further
The markets try to figure out who really benefits from last week’s patent decision over a key mRNA technology.
Medtech
The UK bets on Nanopore and Nudge for rapid Covid-19 tests
Fast tests for Covid-19 infections could be very useful – but only if they are accurate.
Healthineers makes its ambition plain with $16.4bn Varian buy
Suddenly 2020’s medtech M&A landscape looks very different.
Company Events
Go or no go? Valuable drugs set for FDA decisions
Upcoming US approval verdicts include inclisiran, valrox and risdiplam, but toxicity issues could scupper filgotinib.
Alzheimer’s catalysts round off a year dominated by Biogen
Clinical data near for Alzheimer’s antibodies from Roche and Lilly, while Cortexyme and Biohaven test small molecules.
Go or no go? Pandemic looms over FDA timelines
Approval decisions are due for Jazz, Gilead and Galapagos in July, while Glaxo is preparing for a panel.
Interviews
Healthineers’ Covid-19 antibody test spikes an interest in vaccines
The German group has come late to antibody testing, but has punchy accuracy data and a possible means of neutralising some of the competition.
Making sense of Covid-19 treatment approaches
IGM's Dan Chen, an expert on coronaviruses, speaks about the value of different ways of trying to treat Covid-19.
Zynerba hopes to crack fragile X at last
The next few months will see data on the cannabinoid Zygel in fragile X syndrome, and a hit – or at least a near miss – will be necessary for more than just approval.